ACRP CP Exam Verified Exam Questions and Answers Latest update
2026/2027
Question:
Crossover
Answer:
when each subject is randomized to a sequence of two or more treatments and hence acts as their own
control for treatment comparisons
Question:
Parallel
Answer:
when subjects are randomized to 1 of 2 or more arms, each arm being allocated a different treatment.
Each treatment will include their investigational product at one or more doses, and one or more control
treatments, such as placebo and/or an active comparator
Question:
A sponsor is developing an IP for treatment of a medical condition where there is one additional
marketed product approved for treatment of the condition. The sponsor believes their product works as
well or better than the current treatment with fewer side effects. What is the most-likely study design
they will use to test the efficacy of the IP?
Answer:
Non- Inferiority
Question:
What type of clinical trial most likely requires enrollment of the largest number of research subjects?
Answer:
Therapeutic confirmatory (aka Pivotal Trial, Ph III, or Comparative Efficacy)
Question:
Minimum number of membors on an IRB/IEC
Answer:
5 .. lay people and medical professionals can be part of the IRB/IEC
Question:
Who is responsible for providing the protocol
Answer:
The Sponsor
, Question:
The purpose of the SIV is to
Answer:
review standard procedures
-review the protocol
-review the blank eCRFs
Question:
Minimum SAE reporting requirements
Answer:
Subject details (ID not name)
- IP
- Interventions for the event that is being reported
- Details of the event
- Details on the reporter of the event
- Admin and sponsor or company details/
Question:
Vulnerable subjects
Answer:
Junior members of the medical profession
- Employees of a pharmaceutical company
- Military personnel
- Pregnant Women
- Prisoners
Question:
IRB/IEC Evaluates
Answer:
The rights, safety, and well-being of the subjects participating in the trial
- The subject selection procedure
- The scientific tenability of the trial
2026/2027
Question:
Crossover
Answer:
when each subject is randomized to a sequence of two or more treatments and hence acts as their own
control for treatment comparisons
Question:
Parallel
Answer:
when subjects are randomized to 1 of 2 or more arms, each arm being allocated a different treatment.
Each treatment will include their investigational product at one or more doses, and one or more control
treatments, such as placebo and/or an active comparator
Question:
A sponsor is developing an IP for treatment of a medical condition where there is one additional
marketed product approved for treatment of the condition. The sponsor believes their product works as
well or better than the current treatment with fewer side effects. What is the most-likely study design
they will use to test the efficacy of the IP?
Answer:
Non- Inferiority
Question:
What type of clinical trial most likely requires enrollment of the largest number of research subjects?
Answer:
Therapeutic confirmatory (aka Pivotal Trial, Ph III, or Comparative Efficacy)
Question:
Minimum number of membors on an IRB/IEC
Answer:
5 .. lay people and medical professionals can be part of the IRB/IEC
Question:
Who is responsible for providing the protocol
Answer:
The Sponsor
, Question:
The purpose of the SIV is to
Answer:
review standard procedures
-review the protocol
-review the blank eCRFs
Question:
Minimum SAE reporting requirements
Answer:
Subject details (ID not name)
- IP
- Interventions for the event that is being reported
- Details of the event
- Details on the reporter of the event
- Admin and sponsor or company details/
Question:
Vulnerable subjects
Answer:
Junior members of the medical profession
- Employees of a pharmaceutical company
- Military personnel
- Pregnant Women
- Prisoners
Question:
IRB/IEC Evaluates
Answer:
The rights, safety, and well-being of the subjects participating in the trial
- The subject selection procedure
- The scientific tenability of the trial
